Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.67 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.43 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6662186 | 0.97 | NCF1 (0.63) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL1541501 | 0.90 | NCF1 (0.63) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL29505669 | 0.86 | NCF1 (0.87) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL110927 | 0.86 | NCF1 (0.87) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL13061367 | 0.84 | NCF1 (0.59) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL5722525 | 0.83 | NCF1 (0.58) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL10558443 | 0.82 | KEAP1 (0.53) | NCF1HTR2ATAAR1KMT2AMAPK1 | |
| SCHEMBL8361520 | 0.82 | DRD2 (0.72) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL111234 | 0.80 | NCF1 (1.00) | NCF1ADRA2CDRD2DRD3HTR1A | |
| SCHEMBL6109462 | 0.79 | HTR1A (0.56) | NCF1DRD2DRD3HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952154-B1 | N-acyl and N-aroyl aralkyl amides | PFIZER PROD INC (US) | 2004-08-18 | — | — | EP | claimed |
| US-6323229-B1 | COMPOUNDS ARE USEFUL PSYCHOTHERAPEUTICS AND ARE POTENT AGONISTS AND/OR ANTAGONISTS OF THE SEROTONIN 1A (5-HT 1A) AND/OR SEROTONIN 1D (5-HT 1D) FOR TREATMENT OF HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER | PFIZER INC | 2001-11-27 | — | — | US | claimed |
| EP-0952154-A2 | N-acyl and N-aroyl aralkyl amides | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-2167491-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | Abbott Laboratories (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154241-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | WO | disclosed |
| EP-1753460-A2 | COMBINATION OF ATYPICAL ANTIPSYCHOTICS AND 5-HT1B RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1737466-A1 | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1703918-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050256112-A1 | Combination of atypical antipsychotics and 5HT-1B receptor antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
| WO-2005107808-A2 | COMBINATION OF ATYPICAL ANTIPSYCHOTICS AND 5-HT1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005082372-A1 | COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050182049-A1 | Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists | PFIZER INC | 2005-08-18 | — | — | US | disclosed |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | PFIZER INC | 2005-08-04 | — | — | US | disclosed |
| WO-2005067973-A2 | COMBINATION OF CRF ANTAGONISTS AND 5-HT 1B RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-07-28 | — | — | WO | disclosed |
| EP-0952154-B1 | N-acyl and N-aroyl aralkyl amides | PFIZER PROD INC (US) | 2004-08-18 | — | — | EP | disclosed |
| US-6451803-B1 | N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders | PFIZER INC | 2002-09-17 | — | — | US | disclosed |
| US-6323229-B1 | COMPOUNDS ARE USEFUL PSYCHOTHERAPEUTICS AND ARE POTENT AGONISTS AND/OR ANTAGONISTS OF THE SEROTONIN 1A (5-HT 1A) AND/OR SEROTONIN 1D (5-HT 1D) FOR TREATMENT OF HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER | PFIZER INC | 2001-11-27 | — | — | US | disclosed |
| US-6197773-B1 | HEADACHES; ANTIDEPRESSANTS | PFIZER INC | 2001-03-06 | — | — | US | disclosed |
| EP-0952154-A2 | N-acyl and N-aroyl aralkyl amides | Pfizer Products Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256112-A1 | Combination of atypical antipsychotics and 5HT-1B receptor antagonists | HTR1B, HTR2B, HTR3B | NCF1 4861/4885ADRA2C 29/4885DRD2 49/4885 |
| US-20050182049-A1 | Combination of gamma-aminobutyric acid modulators and 5-HT1B receptor antagonists | HTR1B, HTR2B, HTR2A | NCF1 4849/4885ADRA2C 38/4885DRD2 259/4885 |
| US-20050171095-A1 | Combination of CRF antagonists and 5-HT1B receptor antagonists | HTR2B, HTR1B, HTR3B | NCF1 4525/4885ADRA2C 46/4885DRD2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.